Prostate cancer chemoprevention by silibinin: bench to bedside

Area of Science:

• Oncology
• Molecular Biology
• Natural Products Chemistry

Background:

• Prostate cancer (PCA) is a leading cause of cancer deaths in American males.
• Targeting mitogenic and survival signaling pathways, along with cell-cycle regulation, is a key strategy for PCA prevention and intervention.
• Overexpression of receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases drives uncontrolled PCA cell growth and progression.

Purpose of the Study:

• To investigate the potential of silibinin, a naturally occurring flavonoid, as a therapeutic agent for prostate cancer.
• To determine the molecular targets and mechanisms of action of silibinin in PCA.
• To evaluate the efficacy of silibinin in preclinical models of prostate cancer.

Main Methods:

• In vitro studies on PCA cells from human, mouse, and rat origins.
• In vivo studies using human prostate tumor xenografts in nude mice.
• Assessment of silibinin's effects in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
• Analysis of silibinin's impact on epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), NF-kappaB, and cell-cycle regulators (CDKs, cyclins).

Main Results:

• Silibinin effectively targets EGFR, IGF-1R, and NF-kappaB pathways in PCA.
• Silibinin modulates cell-cycle regulators, including cyclin-dependent kinases (CDKs) and cyclins, contributing to its anticancer efficacy.
• Silibinin inhibits the growth of PCA cells and suppresses tumor xenograft growth in mice.
• Silibinin demonstrates efficacy in the TRAMP mouse model of prostate cancer.

Conclusions:

• Silibinin exhibits significant anticancer activity against prostate cancer through multiple molecular targets.
• The natural flavonoid silibinin represents a promising, non-toxic agent for PCA prevention and intervention.
• Preliminary clinical trial data suggest silibinin warrants further investigation in a larger patient population.